BioCryst Pharmaceuticals Inc (BCRX) bonds
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.50+0.05 (+0.67%)
Close on Nov 17, 2026Market cap $1.92BP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$395.40M
Long-term debt
Net debt
$240.43M
After $154.97M of cash
Implied interest rate
50.10%
FY2025 interest ÷ average debt
Interest coverage
4.3×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2019
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in BioCryst Pharmaceuticals's 10-Q for the period ended Jun 30, 2026
BioCryst Pharmaceuticals's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed. The repayment schedule above comes from the same report.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Drawn |
|---|---|---|
| Blackstone | $400.00M | $400.00M |
| Blackstone Loan Agreement | $400.00M | – |
| Credit Agreement | $200.00M | $240.45M |
| Loan Agreement | $450.00M | – |
| Term Loan Tranche B | $50.00M | – |
| Term Loan Tranche C | $50.00M | – |
| Term Loan Tranche D | $50.00M | – |
See a number that looks wrong?